Dabigatran approved in Japan for atrial fibrillation
This article was originally published in Scrip
Boehringer Ingelheim's novel, oral direct thrombin inhibitor dabigatran etexilate has been approved for sale in Japan.It will be launched under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan for nearly 50 years, according to the company.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.